Kidney Protective Effects of Glucagon-Like Peptide-1 Receptor Agonists Versus Sodium/Glucose Cotransporter 2 Inhibitors in Persons With Diabetes and CKD: Implications for Personalized Medicine
Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists and Sodium/Glucose Cotransporter 2 Inhibitors in Preventing Chronic Kidney Failure and Mortality in Patients With Type 2 Diabetes and CKD